Downloads
Abstract
Objective: To evaluate the change of Alpha – Fetoprotein (AFP) levelsin the therapy process, in order to assess the efficiency of surgery and chemotherapy and a prognosis factor in children's hepatoblastoma treatment.
Methods: Pre- respective study. This study focuses on 31 children hospitalized in Pediatric Hospital I, Il from January 2002 to April 2014, who were operated on and received chemotherapeutic treated post-op. followed by the same research pattern.
Results: There were two groups: the survivors and the fatalities. In the survivor group, the difference of AFP level only appeared in cyacle 2, 3 with p<0.05, and had a special meaning in cycle 4 with p = 0.000. In this group, the AFP level decreased very quickly from cycle 1 to cycle 2, went down to normal digit at cycle 3and oscillatedaround the normal digit after 4 cycles. In the death group, the AFP level decreased at first, but it quickly increased at the end of the last cycle.
Conclusion: The AFP level is much higher than 20ng/ml in all hepatoblastom children. Increasing the AFP level about ≥ 2logs or decreasing ≤ ten squared is a good prognosis in hepatoblastoma treatment process. The changing of AFP level help us to assess good efficiency or discover local relapsedtumorsor lung metastases.
References
Abelev GT, et al (1967), “Embryonal serum alpha-globulin in cancer patients: Diagnostic value”. J Cancer Int, 2(5), pp. 551-558.
Feusner JH, Hass JE, et al. (1993), “Treatment of pulmonary metastases of initial stage I hepatoblastoma in childhood”, Cancer, (71), pp. 859-864.
Koh KN, Park M, Kim BE, et al (2011), “Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma”, Pediatr Blood Cancer. 57(4), pp. 554-60.
Malogolowkin MH, Katzenstein HM, Krailo MD, et al (2006), “Intensified platinum therapy is an ineffective strategy for improving the outcome in pediatric patients with advanced hepatoblastoma”. J Clin Oncol, 24 (18), pp. 2879-84.
Malogolowkin MH, Katzenstein HM, Krailo MD, et al (2008), “Redefining the role of doxorubicin for the treatment of children with hepatoblastoma”. J Clin Oncol. 10, pp. 2379-2383.
Ortega JA, Douglass EC, Feusner JH, et al. (2000), “Randomized comparison of cisplatin / vincristine / fluorouracil and cisplatin / continuous infusion doxorubicin for treatment of pediatric hepatoblastoma”: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 18 (14), pp. 2665-75.
Reynolds M, Douglass EC, Finegold M, et al, (1992) “Chemotherapy can convert unresectable hepatoblastoma”. J Pediatr Surg, 27(8), pp. 1080-3; discussion 1083-4.
Van Tornout JM, Buckley JD, Quinn JJ, et al (1997), “Timing and magnitude of decline in AFP levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the children’s cancer group”. J Clin Oncol, 15, pp. 1190 – 7.
Warmann SW, Fuchs J (2007), “Drug resistance in hepatoblastoma”. Curr. Pharm. Biotechnol. 8, pp: 93-97.
| Published | 19-08-2016 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 36 (2016) | |
| Section | Original article | |
| DOI | ||
| Keywords | Alpha-Fetoprotein (AFP), chemotherapy, surgery, cycle |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital